our Approach & context

The prevention and treatment of chronic
and acute pain

The results obtained with TAFA4 in preclinical studies show the strong antalgic potential of this protein in the treatment of chronic postoperative pain and neuropathic pain. Chronic and acute pains represents a real challenge due to its frequency. The lack of effective treatment is an important sociological issue for patients well-being. Moreover, in addition to being invalidating chronic pain also affects the morale of patients who are more susceptible to develop depression.

CHRONIC pain

Chronic Postoperative Pain (CPOP) is an economical and social issue because it leads to a high healthcare costs as well as significant absenteeism.

One patient out of 5 develops PCOD.

In France, each year, approximately 500,000 people are concerned by PCOD, and its impact on the patient’s quality of life is significant. Because PCOD is still poorly undestood and under-diagnosed, it represents a major issue for the healthcare systems.

Chronic postoperative pain also represents a major public health issue affecting 10 to 50% of patients undergoing surgery and 2 to 10% suffer from acute pain.

It is one of the main reasons for consultation in the pain control structures. Amputation, breast cancer, thoracic and herniated disc surgeries are the most likely causes of induced- chronic pain. Surgery is the second most common cause of neuropathic pain after lumbar pain in the general population.

Millions

surgeries performed by year in the world

Including

0 %

People

that undergo a surgery are concerned by chronic pain. It is one of the major motives for consultation in pain clinics.

Neuropathic Pain

Neuropathic pain is characterized by unpleasant symptoms such as shooting pain or burning sensation, numbness, altered sensation and sensations that are very difficult to describe.

According to the International Association for the Study of Pain , neuropathic pain is the direct result of an injury or disease affecting the somatosensory system. For the majority of neuropathic pain, there is no effective treatment in time, and some are even refractory to the most powerful analgesics such as morphine or tramadol. Most often, anti-epileptics or anti-depressants are prescribed despite their associated side effects.

According to the STOPNEP epidemiological survey (« Study of the Prevalence of Neuropathic Pain »), carried out in France (source: Livre Blanc de la Douleur), the prevalence of neuropathic pain in France represents 7% of the population of which 5% have moderate to severe pain.